» Articles » PMID: 2225705

Quality of Life Among Hypertensive Patients with a Diuretic Background Who Are Taking Atenolol and Enalapril

Overview
Publisher Wiley
Specialty Pharmacology
Date 1990 Oct 1
PMID 2225705
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

The cardioselective beta-blocker atenolol and the angiotensin-converting enzyme inhibitor enalapril were compared for efficacy, safety, and quality-of-life factors in 30 patients with hypertension whose hypertension was inadequately controlled with diuretic alone. Atenolol (50 to 100 mg once a day) and enalapril (2.5 to 40 mg once a day), combined with hydrochlorothiazide (25 mg once a day), had similar levels of efficacy and safety. A comprehensive battery of psychologic assessments for quality of life was administered, including measures of anxiety, depression, psychiatric symptoms, memory, and psychomotor function. These five conceptually based clusters were first analyzed by multivariate analysis of variance procedures, followed by univariate analyses of the individual variables composing each domain. In general, neither atenolol nor enalapril was associated with major changes in psychologic functioning. The only data cluster with a statistically significant change was memory function, primarily as a result of lower scores of the digit span (backward) test, for atenolol relative to enalapril. These preliminary findings suggest that atenolol and enalapril have comparable degrees of efficacy and safety, with no major disparities in quality-of-life effects, for hypertensive patients with a history of taking diuretics and this sort of quality-of-life assessment can be performed during trials of antihypertensive drugs.

Citing Articles

Health-related quality-of-life measurement in hypertension. A review of randomised controlled drug trials.

Cote I, Gregoire J, Moisan J Pharmacoeconomics. 2001; 18(5):435-50.

PMID: 11151397 DOI: 10.2165/00019053-200018050-00003.


Enalapril: a review of quality-of-life and pharmacoeconomic aspects of its use in heart failure and mild to moderate hypertension.

Wilde M, Bryson H, Goa K Pharmacoeconomics. 1994; 6(2):155-82.

PMID: 10147441 DOI: 10.2165/00019053-199406020-00008.


Assessing the responsiveness of a quality-of-life instrument and the measurement of symptom severity in essential hypertension.

Reilly M, Zbrozek A Pharmacoeconomics. 1992; 2(1):54-66.

PMID: 10146979 DOI: 10.2165/00019053-199202010-00007.


Quality of life claims in trials of anti-hypertensive therapy.

Hunt S Qual Life Res. 1997; 6(2):185-91.

PMID: 9161118 DOI: 10.1023/a:1026498318938.


The effect of antihypertensive treatment on the quality of later years.

James M, Potter J Drugs Aging. 1993; 3(1):26-39.

PMID: 8453183 DOI: 10.2165/00002512-199303010-00003.